• 1
    Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents – March 27, 2012. Available at (accessed 11 June 2013).
  • 2
    Thompson MA, Aberg JA, Hoy JF et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308: 387402.
  • 3
    Elzi L, Erb S, Furrer H et al. Choice of initial combination antiretroviral therapy in individuals with HIV infection: determinants and outcomes. Arch Intern Med 2012; 172: 13131321.
  • 4
    Knobel H, Guelar A, Valldecillo G et al. Response to highly active antiretroviral therapy in HIV-1 infected patients aged 60 years or older after 24 months of follow up. AIDS 2001; 15: 15911593.
  • 5
    Grabar S, Kousignian I, Sobel A et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS 2004; 18: 20292038.
  • 6
    Silverberg MJ, Leyden W, Horberg MA et al. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med 2007; 167: 684691.
  • 7
    Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group. Response to combination antiretroviral therapy: variation by age. AIDS 2008; 22: 14631473.
  • 8
    Blanco JR, Jarrin I, Vallejo M et al. Definition of advanced age in HIV-infection: looking for an age cut-off. AIDS Res Hum Retroviruses 2012; 28: 10001006.
  • 9
    Daar ES, Tierney C, Fischl MA et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154: 445456.
  • 10
    Sobrino-Vegas P, Gutierrez F, Berenguer J et al. [The Cohort of the Spanish HIV Research Network (CoRIS) and its associated biobank; organizational issues, main findings and losses to follow-up]. Enferm Infecc Microbiol Clin 2011; 29: 645653.
  • 11
    Prentice RL, Kalbfleisch JD, Peterson AV, Jr et al. The analysis of failure times in the presence of competing risks. Biometrics 1978; 34: 541554.
  • 12
    Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007; 26: 23892430.
  • 13
    Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496509.
  • 14
    Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol 2009; 170: 244256.
  • 15
    Geskus RB. Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring. Biometrics 2011; 67: 3949.
  • 16
    Kharasch ED, Whittington D, Ensign D et al. Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2012; 91: 673684.
  • 17
    Bentue-Ferrer D, Arvieux C, Tribut O et al. Clinical pharmacology, efficacy and safety of atazanavir: a review. Expert Opin Drug Metab Toxicol 2009; 5: 14551468.
  • 18
    Torti C, Maggiolo F, Patroni A et al. Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort. J Antimicrob Chemother 2005; 56: 190195.
  • 19
    Di BA, Prinapori R, Giannarelli D et al. Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort. J Antimicrob Chemother 2013; 68: 200205.
  • 20
    Riddler SA, Haubrich R, DiRienzo AG et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358: 20952106.
  • 21
    Antiretroviral Therapy Cohort Collaboration (ART-CC). Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002–2009. AIDS 2013; 27: 803813.
  • 22
    Squires KE, Young B, DeJesus E et al. ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine. HIV Clin Trials 2012; 13: 233244.
  • 23
    Vo TT, Ledergerber B, Keiser O et al. Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 2008; 197: 16851694.
  • 24
    Elzi L, Marzolini C, Furrer H et al. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 2010; 170: 5765.
  • 25
    Lubomirov R, Colombo S, di Iulio J et al. Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis 2011; 203: 246257.
  • 26
    d'Arminio MA, Lepri AC, Rezza G et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000; 14: 499507.
  • 27
    Mocroft A, Youle M, Moore A et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001; 15: 185194.
  • 28
    Puls RL, Srasuebkul P, Petoumenos K et al. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis 2010; 51: 855864.
  • 29
    Squires K, Lazzarin A, Gatell JM et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36: 10111019.
  • 30
    Althoff KN, Justice AC, Gange SJ et al. Virologic and immunological response to HAART, by age and regimen class. AIDS 2010; 24: 24692479.
  • 31
    Lang S, Mary-Krause M, Cotte L et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170: 12281238.
  • 32
    Winston A, Jose S, Gibbons S et al. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. J Antimicrob Chemother 2013; 68: 13541359.
  • 33
    Patterson K, Napravnik S, Eron J et al. Effects of age and sex on immunological and virological response to initial highly active antiretroviral therapy. HIV Med 2007; 8: 406410.